Trial · NCT03614273
Nebulized Hypertonic Saline (3%) Versus Nebulized Adrenaline for Treatment of Bronchiolitis
NCT03614273, Not applicable, Completed, Maulana Azad Medical College
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Nebulized Hypertonic Saline (3%) Versus Nebulized Adrenaline for Treatment of Bronchiolitis. Trials, record NCT03614273. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03614273
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Nebulized Hypertonic Saline (3%) Versus Nebulized Adrenaline for Treatment of Bronchiolitis
- NCT number
- NCT03614273
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 60 participants, actual
- Lead sponsor
- Maulana Azad Medical College
- Conditions
- Bronchiolitis
- Interventions
- Hypertonic saline, Adrenaline
- First posted
- 2018-08-03
- Last updated
- 2018-08-03
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Duration of hospital stay | During hospitalization, approximately 2 days | Duration from the time of enrolment to the point at which the discharge criteria (feeding well orally, no need for intravenous fluids, clinical severity score ≤ 3 and maintaining oxygen saturation \>92% on room air for a period of more than 12 hours) are met. |
| Secondary | Initial change in the Wang bronchiolitis clinical severity score | 20 minutes after the first nebulization | A decrease in the Wang bronchiolitis clinical severity score by at least 3 points after 20 minutes of nebulization was considered as an improvement in the clinical condition. The Wang score ranges from 0 - 12 \[0-4: mild, 5-8: moderate, 9-12: severe\]. |
| Secondary | Number of hours of intravenous fluid requirement | During hospitalization, approximately 2 days | Intravenous fluids were given to children unable to accept orally. |
| Secondary | Number of hours of oxygen requirement | Till the time the child maintained a saturation of more than 94% for at least 4 hours | Oxygen was administered when the saturation was less than 92% |
| Secondary | Number of doses of nebulization needed | During hospitalization, approximately 2 days | Indications for repeat dose were if: 1. The child had severe audible wheeze with severe respiratory distress (severity score ≥9) 2. The child was not able to maintain saturation \>92% even on an oxygen flow of 4 L/min |
| Secondary | Response after each nebulization | Assessed 20 minutes after each nebulization | An improvement in the clinical severity score by at least 3 points after each nebulization. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03614273
GET https://conductscience.org/api/trials/v1/NCT03614273/registered